

Criteria Grid
Hepatitis C Research Studies, Tools, and Surveillance Systems

Best Practice/Intervention:	Alavian SM. et al. (2010) Hepatitis C infection in hemodialysis patients in Iran: a systematic review. <i>Hemodialysis International</i> , 14(3):253-262			
Date of Review:	March 10, 2015			
Reviewer(s):	Christine Hu			
Part A				
Category:	Basic Science <input type="checkbox"/> Clinical Science <input type="checkbox"/> Public Health/Epidemiology <input type="checkbox"/> Social Science <input type="checkbox"/> Programmatic Review <input checked="" type="checkbox"/>			
Best Practice/Intervention:	Focus: Hepatitis C <input checked="" type="checkbox"/> Hepatitis C/HIV <input type="checkbox"/> Other: _____ Level: Group <input checked="" type="checkbox"/> Individual <input type="checkbox"/> Other: _____ Target Population: <u>hemodialysis patients with HCV in Iran</u> Setting: Health care setting/Clinic <input checked="" type="checkbox"/> Home <input type="checkbox"/> Other: _____ Country of Origin: <u>Iran</u> Language: English <input checked="" type="checkbox"/> French <input type="checkbox"/> Other: _____			
Part B				
	YES	NO	N/A	COMMENTS
<i>Is the best practice/intervention a meta-analysis or primary research?</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	meta-analysis; systematic review to estimate the prevalence of hepatitis C infection in Iranian hemodialysis patients
<i>Has the data/information been used for decision-making (e.g. program funding developments, policies, treatment guidelines, defining research priorities and funding)?</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Author mentioned that the data may play a part in involving organizations of prevention programs and their planning according to the natural characteristics of each Iranian province to reduce HCV infection prevalence in Iranian hemodialysis patients
<i>Do the methodology/results described allow the reviewer(s) to assess the generalizability of the results?</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

<i>Are the best practices/methodology/results described applicable in developed countries?</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Similar studies could be done in other countries using similar methodology. This review only studied the prevalence of HCV in hemodialysis patients in Iran, therefore the results may not be applicable to other countries.
	YES	NO	N/A	COMMENTS
<i>Are the best practices/methodology/results described applicable in developing countries?</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
<i>The research study/tool/data dictionary is easily accessed/available electronically</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Available to download from http://onlinelibrary.wiley.com
<i>Is there evidence of cost effective analysis with regard to interventions, diagnosis, treatment, or surveillance methodologies? If so, what does the evidence say? Please go to Comments section</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
<i>Are there increased costs (infrastructure, manpower, skills/training, analysis of data) to using the research study/tool/data dictionary?</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
<i>How is the research study/tool funded? Please got to Comments section</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	The work was supported and funded by the Research Center for Liver Diseases and Gastroenterology, Baqiyatallah University of Medical Sciences and Health Services, Tehran, Iran, and supported by the Nikan Health Researchers Institute, NHRI, Tehran, Iran
<i>Is the best practice/intervention dependent on external funds?</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
<i>Other relevant criteria:</i> _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	- Did not include studies from south or east of Iran
WITHIN THE SURVEILLANCE SYSTEM FOR REVIEW				
<i>Are these data regularly collected?</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	laboratory tests for finding the presence of positive HCV antibody in blood samples done from April 2001 to March 2008
<i>Are these data regularly collected at and/or below a national level?</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	

<i>Are these data collected manually or electronically?</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Data collected both electronically and manually
RESEARCH REPORTS				
<i>Has this research been published in a juried journal?</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Hemodialysis International</i>
<i>Does the evidence utilize the existing data/surveillance information or has it generated new data and/or information?</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Existing data/surveillance: use reports of HCV infection prevalence in specific regions or selected groups in Iran

Review Article

Hepatitis C infection in hemodialysis patients in Iran: A systematic review

Seyed-Moayed ALAVIAN,¹ Ali KABIR,^{2,3} Amir Bahrami AHMADI,² Kamran Bagheri LANKARANI,⁴ Mohammad Ali SHAHBABAIE,² Masoud AHMADZAD-ASL²

¹Department of Gastroenterology and Hepatology, Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, Iran; ²Department of Applied Researches, Nikan Health Researchers Institute, Tehran, Iran; ³Medical Education Department, Iran University of Medical Sciences, Tehran, Iran; ⁴Department of Gastroenterology and Hepatology, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Hemodialysis (HD) patients are recognized as one of the high-risk groups for hepatitis C virus (HCV) infection. The prevalence of HCV infection varies widely between 5.5% and 24% among different Iranian populations. Preventive programs for reducing HCV infection prevalence in these patients require accurate information. In the present study, we estimated HCV infection prevalence in Iranian HD patients. In this systematic review, we collected all published and unpublished documents related to HCV infection prevalence in Iranian HD patients from April 2001 to March 2008. We selected descriptive/analytic cross-sectional studies/surveys that have sufficiently declared objectives, a proper sampling method with identical and valid measurement instruments for all study subjects, and proper analysis methods regarding sampling design and demographic adjustments. We used a meta-analysis method to calculate nationwide prevalence estimation. Eighteen studies from 12 provinces (consisting 49.02% of the Iranian total population) reported the prevalence of HCV infection in Iranian HD patients. The HCV infection prevalence in Iranian HD patients is 7.61% (95% confidence interval: 6.06–9.16%) with the recombinant immunoblot assay method. Iran is among countries with low HCV infection prevalence in HD patients.

Key words: Hepatitis C, hemodialysis, prevalence, Iran

INTRODUCTION

Hepatitis C virus (HCV) infection is one of the main health problems worldwide.^{1–3} Hemodialysis (HD) patients belong to high-risk groups for HCV infection and have a significantly higher HCV prevalence than the general population.^{4,5} HCV infection has been recognized as an emerging problem in dialysis patients and its prevalence varies considerably among different regions of the world. HD patients are at a risk of HCV infection due to

some factors such as impairment of their cellular immunity, blood transfusion, frequent hospitalization, and underlying diseases such as diabetes or chronic renal failure. These factors increase chances of exposure to nosocomial infection.^{6,7} HCV has an impact on the life expectancy of HD patients. HD patients with HCV infection have 1.4 times more chance of dying than uninfected HD patients.⁸

The percentage of HCV prevalence in HD patients varies across several countries and even across dialysis centers.⁹ HCV infection prevalence in HD patients is between 7% and 40% in some developed countries.^{10,11} HCV infection prevalence in Iranian HD patients is higher than that in the general population.^{12,13} This infection prevalence varies widely from 5.5% to over 24% among different Iranian provinces.^{13–15}

Correspondence to: S.-M. Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Grand floor of Baqiyatallah Hospital, Mollasadra Ave., Vanak Sq. PO Box 14155-3651, Tehran, Iran.
E-mail: editor@hepmon.com

We do not have an overall estimation of HCV infection prevalence in HD patients in Iran. Current studies have reported HCV infection prevalence in specific regions or selected groups. The overall estimation of HCV infection in the general population will help health policymakers create or modify prevention programs for Iranian HD patients. In the present systematic review, we have reviewed papers and reports related to HCV infection prevalence in an Iranian general population.

MATERIAL AND METHODS

We estimated the prevalence of HCV in an Iranian general population in a comprehensive systematic review of literature and evidences, followed by integration of data and analysis of the findings.

Study question

Our study population comprised an Iranian general population, and the desired outcome was the presence of a positive HCV antibody in blood samples of the study population, based on any blood test such as enzyme-linked immunosorbent antibody (ELISA) or recombinant immunoblot assay (RIBA)/polymerase chain reaction (PCR), although other laboratory tests have not been identified clearly, from April 2001 to March 2008.

Search strategy

For electronic and hand search, we used key words such as "Hepatitis C," "HCV," and "Iran" (or names of its provinces) in the titles and/or the abstracts as MeSH words. We also used different textwords (specifically when searching national databases) to increase the sensitivity of the search. After obtaining all papers on HCV prevalence in Iran, we used the word "hemodialysis" for extracting related papers on the prevalence of HCV in hemodialysis patients.

Electronic databases

We searched 15 electronic databases of health and biological sciences including Google Scholar, ISI, Scopus, EMBASE, Medline, WHO, CINAHL, DOAJ, CABI, High-Wire Press, EBM Review, EMRmedex, Cochrane, NLM Gateway, and DARE. Furthermore, four Iranian databases of the medical and life sciences literature were used, including Iranmedex, SID, Magiran, and IranDoc. Hence, the study covered all registered and certified life sciences and medical journals at the national level.

Gray literature search

In the gray literature search, we found 243 national, regional, and international Iranian medical science congresses in the study time period. Sixty-seven out of 243 relevant congress' abstract books were selected and hand searched by 2 independent reviewers. We also searched the research projects of 29 out of 40 Iranian universities of medical sciences from their websites. We contacted the Center for Diseases Control (CDC) of the Iran Ministry of Health and Iran Blood Transfusion Organization (IBTO) for searching national reports in the study time period. Medical students' theses were also evaluated by 2 independent reviewers from the Iranian center for scientific documents and records (IranDoc). Finally, we consulted 8 experts in HCV researchers in Iran and searched their personal archives for additional citations. Forward and backward citations of the searched items were also performed.

Critical appraisal and selection of studies

We revised the criteria developed by V. Sharifi et al (unpublished data) for this purpose. All citations were reviewed thoroughly by 2 independent reviewers and checked for eligibility criteria to include the studies in the analysis. The inclusion criteria were all descriptive/analytical cross-sectional studies/surveys that has specified temporal and geographic specifications of the study, sufficiently declared objectives, proper sampling methods that could generalize findings to the target population with valid measurement instruments for all study subjects, and proper analysis methods regarding the sampling design and demographic properties. Studies that did not fulfill these specifications were not included in our meta-analysis due to low quality.

Data extraction

After study evaluation, we included studies and extracted findings to excel spreadsheets. The extracted data included the year of the study, first author, province and district of the study, sample population, sampling method, sample size, HCV antibody detection method, HCV antibody kit name, mean age and standard error (SE) of subjects, percentage of male subjects, HCV point prevalence in study subjects and/or in males/females, and its SE. If parameters other than SE were reported, such as standard deviation, confidence interval (CI), and/or P value, proper modifications were performed to calculate the SE.

Statistical analysis

We analyzed extracted data to estimate the point prevalence of HCV infection and its 95% CI, and used the Cochrane Q test with a significance level of <0.1 for checking the statistical heterogeneity of the results. We used the meta-analysis method with the “meta” command using a fixed/random model based on the results of the heterogeneity test. The analysis was performed using STATA 9.1 software (STATA Corp. LP, TX, USA). The results are shown in geographic maps using Arc View 3.2a software (ESRI Inc., New York, NY, USA).

RESULTS

Search results

In our primary search in electronic databases with our search strategy, we found 6431 documents. After assessing documents according to their titles and abstracts, we

excluded 6143 unrelated documents. We assessed the rest of the 288 studies, and after reading their full texts, we excluded 98 unrelated or duplicated documents again. We added gray literature (68 congress documents and 11 medical theses) to the rest of the documents. Among the congress documents, five were of low quality, 13 were unrelated, and 39 were published as papers and found in a previous database. In medical theses, 2 documents were duplicated. At this stage, 11 congress documents and 9 medical theses were added to the rest of the documents and included 220 unduplicated and relevant to HCV infection prevalence documents. Finally, 18 documents relevant to HCV prevalence in Iranian HD patients remained in our database (Diagram 1).

Studies

After excluding duplicate and overlapping reports to avoid double counting, we finally selected 18 studies (15 published and 3 unpublished studies) from twelve provinces




Diagram 1 Systematic review and searches for hepatitis C virus (HCV) infection prevalence in Iranian hemodialysis patients.

with Iranian HD patients as subjects^{16–33} (Diagram 1). The 12 provinces that were studied in our study consisted of 49.02% of the Iranian total population.³⁴

HCV infection prevalence

According to official reports of the Iranian Health Ministry, there are 14413 HD patients in 2666 beds in our country (Iranian Health Ministry, unpublished data) (Table 1). This means that there is 1 dialysis bed for every 5.41 patients. The HCV prevalence range in Iranian provinces varied from 4.9% in Markazi³¹ to 26.4% in Kermanshah.²⁹ The reported percentages were heterogeneous and showed statistical significance (test for heterogeneity: $Q=397.174$, $df=17$, $P<0.001$) (Figure 1).

The overall estimation of HCV prevalence in Iran hemodialysis patients according to the data of 12 provinces was 13.57% (95% CI: 9.86–17.21%) with ELISA and 7.61% (95% CI: 6.06–9.16%) with the RIBA/PCR method (Figure 2). All papers that used ELISA for HCV detection had implemented second or third generations.

DISCUSSION

In the present study, the HCV infection prevalence in Iranian HD patients was 13.57% with ELISA and 7.61% with the RIBA/PCR method. The HCV prevalence in HD patients varies widely in different countries. Although Bahrain has a lower prevalence than Iran, our country is among the countries with the lowest prevalence of HCV in HD patients in the Eastern Mediterranean Region. However, this prevalence is lower than that in most Asian, American, and European countries, except Germany, the United Kingdom, and Australia. The same pattern exists when we consider ELISA as an HCV infection-detecting method; only Germany and England have a lower prevalence than Iran (Table 2).

In our study period from April 2001 to March 2008 and even before that (according to searching in PubMed, Scopus, SID and Iranmedex), our data were restricted to the north, west, and central provinces of Iran. We do not have any studies from provinces that are located in the south or the east of Iran. Next, we need to follow studies in these parts of Iran for a more accurate estimation of HCV prevalence in HD patients. Kermanshah (Western province), Guilan and Golestan (Northern provinces), and West Azarbaijan (Northwest province) had the highest HCV infection prevalence in HD patients.

In our 12 provinces studied, there is one dialysis bed for every 5.68 Iranian HD patients. Provinces with higher HCV infection prevalences (according to RIBA/PCR) such

as West Azarbaijan and Golestan also had a higher dialysis bed usage rate than its national average. Kermanshah and Guilan had a high HCV prevalence but it was not higher than the national dialysis bed usage. This may be due to the method of evaluating HCV infection (ELISA and not determined, respectively), which can be interpreted as a falsely high HCV infection prevalence. Both Semnan and Markazi (Central provinces) have a lower HCV infection prevalence and a lower dialysis bed usage rate, which seems completely logical and is probably due to better accessibility to dialysis beds and having less contact with neighbors of Iran due to their geographical location. However, some provinces such as Ghazvin have a higher usage of dialysis bed units but a lower HCV prevalence. It seems that there are some other prevention modalities in these provinces for HCV infection control (Table 1).

According to the data presented in Table 1, there is a discrepancy (in East Azarbaijan) between the results of RIBA and ELISA in detecting HCV prevalence. This difference might be due to the nature (screening or confirmatory) of these tests. HCV prevalences in HD patients of western and northern provinces were higher than those of central provinces. Factors such as hepatitis care plans, usage rate of dialysis beds, dialysis durations, and HCV-detecting tests may be responsible for these rates (Table 1). Differences in HCV infection prevalence might be due to local risk factors in different Iranian regions.⁴⁵

Different sources play important roles in HCV infection transmission in HD patients and units. Transmission of HCV in HD patients was associated with blood transfusion in the past.^{46,47} But in recent years, the need for transfusion in HD patients has decreased due to enhanced safety of blood products, although HCV infection has been proven to still be in circulating among HD patients via other routes of transmission.^{48,49} Olmer reported blood transfusion to be a risk factor for HCV infection.⁵⁰ But Forns found no relationship between HCV infection and blood transfusion.⁵¹ Some HCV-infected patients were reported to have no history of blood transfusion.⁵² In Iran, screening of blood donors for anti-HCV started from 1996. In previous reports, blood transfusion was considered to be a risk factor for HCV transmission in Iranian HD patients.^{14,53} Nowadays, blood transfusion does not appear to be a proven risk factor for HCV transmission in Iranian HD patients.⁴⁵

Nosocomial transmission of hepatitis C in HD patients is common in some countries.⁵⁴ Increased number of patients under treatment per unit, patients attending more than one treatment unit, contact with the hepatitis B virus, type of dialysis equipment used and their sterilization, and duration of HD treatment are presented as more important nosocomial transmission risk factors for HCV

Table 1 HCV infection prevalence in several provinces of Iran

Province	Author (year)	Kit	Sample size	Prevalence (95% CI)	Number of patients/ dialysis beds in province ^a	References
All 12 provinces ^b	Present study	PCR/RIBA/ WB/ELISA	5280	12.91 (10.25–15.56)	8238/1451 (5.68)	—
Kermanshah	Saboor et al (2003)	PCR/RIBA/WB	3286	12.19 (9.26–15.12)	308/55 (5.6)	29
Guilan	Mohtasham Amiri et al (2003)	ELISA	560	13.57 (9.89–17.21)	581/94 (6.18)	26
Golestan	Jabbari et al (2008)	ELISA	140	26.4 (17.74–37.73)	419/60 (6.98)	27
West Azarbaijan	Khadem-Ansari and Omrani (2006)	ND	298	24.8 (19.9–29.7)	654/91 (7.19)	33
East Azarbaijan ^b	Somi et al (2008)	RIBA	93	24.7 (16.37–34.76)	769/115 (6.69)	24
		PCR	50	24 (13.06–38.17)		
		PCR	753	7.3 (0.86–26.53)		25
	Taremi et al (2005)	ELISA	324	20.4		35
Qom	Azadegan-Ghomi (2006)	RIBA	236	12.7 (8.74–17.65)	284/65 (4.36)	23
Mazandaran ^c	Taziki and Espahbodi (2008)	ND	1006	12 (9.38–14.22)	685/132 (5.19)	22
	Makhlough et al (2008)	PCR	186	11.3		28
Hamadan	Mohammad Alizadeh et al (2002)	ELISA	96	11.4 (5.26–18.83)	313/50 (6.26)	17
Tehran ^b	Nasiri-Toosi et al (2007)	ND	130	8.5 (7.61–13.71)	3563/661 (5.39)	16
	Boroomand et al (2002)	PCR	548	9.33		18
	Alavian et al (2003)	RIBA	838	13.2		19
Ghazvin ^b	Alavian et al (2001)	RIBA	68	23.9 (2.18–18.42)	207/28 (7.39)	20
	Bozorgi et al (2006)	RIBA	89	6.4		21
	Shadafzar (2007)	RIBA	141	4.96		31
Semnan	Babaie and Saadedin (2004)	RIBA	80	6.25 (2.06–13.98)	149/34 (4.38)	30
Markazi	Samimirad et al (2006)	RIBA	204	4.9 (2.38–8.83)	306/65 (4.71)	

^aStatistics from Transplantation and Specific Disorders Office of Iranian Health Ministry.

^bResults are according to the random model (test of heterogeneity, $P < 0.001$).

^cResults are according to the fixed model (test of heterogeneity, $P > 0.1$).

ELISA = enzyme-linked-immunosorbant antibody; HCV = hepatitis C virus; ND = not determined; PCR = polymerase chain reaction; RIBA = recombinant immunoblot assay; WB = Western blot.




Figure 1 Prevalence of hepatitis C virus (HCV) infection in Iranian hemodialysis patients and different related studies according to recombinant immunoblot assay/polymerase chain reaction for HCV RNA.

infection.^{55,56} The mechanism that is responsible of HCV infection transmission in Iranian HD units has not been understood properly. Some studies have reported that cross infection through dialysis machines may be responsible for HCV infection in our country.¹⁸ It seems that in a prevention program, more attention should be focused on sterilization and control of infection in HD units.

Prevention programs that have been initiated in Iran for evaluation and reduction of HCV infection prevalence in

Iranian HD patients have 3 main parts. The first part involves the diagnosis of all HD patients who are infected with HCV infection and their treatment, even with kidney transplantation.^{8,57} The second part involves education of all nurses and health providers of dialysis centers on HCV infection and transmission routes.⁵⁸ The last part involves organization of prevention programs and their planning according to the natural characteristics of each Iranian province.⁸ Iranian preventive programs will reduce HCV




Figure 2 Prevalence of hepatitis C virus (HCV) in Iranian hemodialysis patients and different provinces of Iran according to a recombinant immunoblot antibody/recombinant immunoblot assay/polymerase chain reaction test.

Table 2 HCV infection prevalence in hemodialysis patients from several papers in the literature

Author (yr)	Country/region	Kit	Sample size	Prevalence %	References
Present study	Iran/EMR	RIBA	5280	12.19	—
		ELISA	5280	13.57	
Souqiyeh et al (2001)	Saudi Arabia/EMR	ELISA	6694	50.49	36
Saxena and Panhotra (2004)	Kuwait/EMR	ND	198	43.3	37
Bdour (2002)	Jordan/EMR	RIBA	283	32.51	38
Khokhar et al (2005)	Pakistan/EMR	ND	97	23.7	39
Yakaryilmaz et al (2006)	Turkey/EMR	ELISA	188	20.2	40
Bergman et al (2005)	USA/America	ND	860	16.8	41
Reddy et al (2005)	India/Asia	RIBA	151	13.23	42
Qadi et al (2004)	Bahrain/EMR	PCR	81	7.4	43
Amin et al (2004)	Australia	RIBA	2800	2.3	44
Fissell et al (2004)	7 European countries and USA ^a	ELISA	8615	Inserted in foot note	11

^aCountries: France (14.7), Germany (3.9%), Italy (22.2%), Japan (19.9%), Spain (22.2%), the United Kingdom (2.7%), and the United States (14%).

ELISA=enzyme-linked-immunosorbant antibody; EMR=Eastern Mediterranean Region; HCV=hepatitis C virus; ND= not determined; RIBA= recombinant immunoblot assay.

infection in Iranian HD patients. Successful control of infection requires further studies to assess the effectiveness of different preventive policies.⁸

Some factors such as treatment of chronic renal patients, screening test in dialysis units, viremia detection in non-HCV-infected HD patients, and better dialysis equipment can help us in the diagnosis and management of HCV infection in HD patients.^{8,59,60}

Several prevention programs were initiated across the world for the prevention and control of HCV infection in HD patients. Some stressed on isolating HD patients^{50,61} and other programs attempted to use some equipment specific for these patients, disinfection of dialysis centers, and the use of consumer tools only for one patient.^{9,62,63} Strict infection control might be sufficient to control HCV infection spread in HD units.^{9,64,65} Calabrese⁶⁶ and Harmankaya⁶⁷ found that dialyzing HCV-infected patients with separate equipment in a dedicated area but not a separate room can reduce the incidence of HCV infection.

The main reason for the heterogeneity in the prevalence of findings in different studies may be the different prevalence in blood donors and general populations in those provinces and different universal infection control precaution status. There is no surveillance system to quantify the HCV infection in HD patients in our country, which is a limitation.

ACKNOWLEDGMENT

This work was performed with the support of and under a research grant from Research Center for Liver Diseases and

Gastroenterology, Baqiyatallah University of Medical Sciences and Health Services, Tehran, Iran, and the support of Nikan Health Researchers Institute, NHRI, Tehran, Iran. The authors wish to thank Mr Vahid Mousavi Davar, Dr Behzad Lotfi, Dr Mohhamad Naeem Bangash, and Nikan Health Researchers Institute (NHRI), Tehran, Iran, for their work and help on search processes, and Mrs Aezam Rostamzad Sereshkeh and Miss. Fatemeh Mohammadi, NHRI, for their follow-up in gray literature search.

Manuscript received October 2009; revised January 2010.

REFERENCES

- 1 Kaldor JM, Dore GJ, Correll PK. Public health challenges in hepatitis C virus infection. *J Gastroenterol Hepatol.* 2000; **15**(Suppl):E83–E90.
- 2 Patrick DM, Buxton JA, Bigham M, Mathias RG. Public health and hepatitis C. *Can J Public Health.* 2000; **91**(Suppl 1):S18–S21.
- 3 Prati F, Lodi V, D'Elia V, Truffelli D, Lalic H, Raffi GB. Screening of health care workers for hepatitis B virus and hepatitis C virus: Criteria for fitness for work. *Arh Hig Rada Toksikol.* 2000; **51**:19–26.
- 4 Barril G. Hepatitis C virus-induced liver disease in dialysis patients. *Nephrol Dial Transplant.* 2000; **15**(Suppl 8):42–45.
- 5 Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: A multi-center study. *J Med Virol.* 2000; **61**:44–51.

- 6 Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Pardo M, Carreno V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. *J Virol*. 2006; **80**:10972–10979.
- 7 Kishi Y, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Makuuchi M. New-onset diabetes mellitus after living donor liver transplantation: possible association with hepatitis C. *Transplant Proc*. 2006; **38**:2989–2992.
- 8 Alavian SM. A shield against a monster: Hepatitis C in hemodialysis patients. *World J Gastroenterol*. 2009; **15**: 641–646.
- 9 Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian multicenter Study. The universitaires cliniques St-Luc (UCL) collaborative group. *Kidney Int*. 1998; **53**:1022–1025.
- 10 Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the united states, 2002. *Semin Dial*. 2005; **18**:52–61.
- 11 Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. *Kidney Int*. 2004; **65**:2335–2342.
- 12 Rezvan H, Ahmadi J, Farhadi M. A preliminary study on the prevalence of anti HCV amongst healthy blood donors in Iran. *Vox Sang*. 1994; **67**(Suppl):100.
- 13 Nobakht-Haghighi A, Zali MR, Nouroozi A. Hepatitis C antibody and related risk factors in hemodialysis patients in Iran. *J Am Soc Nephrol*. 2001; **12**:233A.
- 14 Alavian SM, Einollahi B, Hajjarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. *Nephrology (Carlton)*. 2003; **8**:256–260.
- 15 Rais-Jalali G, Khajehdehi P. Anti-HCV seropositivity among hemodialysis patients of Iranian origin. *Nephrol Dial Transplant*. 1999; **14**:2055–2056.
- 16 Boroomand B, Abdollah-Shamshirsaz AR, Kamgar M, et al. Prevalence of hepatitis C infection and its risk factors in hemodialysis patients in Tehran: Preliminary report from “the effect of dialysis unit isolation on the incidence of hepatitis C in dialysis patients” project. *Saudi J Kidney Dis Transplant*. 2002; **13**:467–472.
- 17 Nasiri-Toosi M, Larti F, Rasteh M, et al. Risk factors and seroprevalence of hepatitis B and C infections among hemodialysis patients in Tehran. *Iran J Pathol*. 2007; **2**: 181–186.
- 18 Alavian SM, Einollahi B, Hajjarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Study of prevalence and risk factors of hepatitis C in hemodialysis patients. *Pajoohandeh*. 2003; **8**:315–319.
- 19 Alavian SM, Sadri M, Hajjarizadeh B, et al. Prevalence and risk factors of hepatitis C in dialysis patients in Qazvin (2001). *J Qazvin Univ Med*. 2004; **7**:16–20.
- 20 Bozorgi SH, Ramezani H, Vahid T, et al. Assessment of prevalence and risk factors of hepatitis C virus infection in haemodialysis patients in Ghazvin. *SJIBTO (Blood J)*. 2006; **2**:331–337.
- 21 ShadAfzar M. *Prevalence and Incidence of Hepatitis C in Hemodialysis Patients in Bo-Ali Medical Center in Qazvin in 2003–2004*. Qazvin: Qazvin University of Medical Sciences and Health Services; 2007.
- 22 Makhloogh A, Mahdavi MR, Haghshenas M, Ghasemian R, Jamshidi M. Hepatitis C prevalence in hemodialysis patients in Mazandaran, Iran: A survey by polymerase chain reaction and serological methods. *Res J Biol Sci*. 2008; **3**:265–268.
- 23 Taziki O, Espahbodi F. Prevalence of hepatitis C virus infection in hemodialysis patients. *Saudi J Kidney Dis Transpl*. 2008; **19**:475–478.
- 24 Somi MH, Keyvani H, Ardalan MR, Farhang S, Poori AA. Hepatitis C virus genotypes in patients with end-stage renal disease in East Azerbaijan, Iran. *Saudi J Kidney Dis Transpl*. 2008; **19**:461–465.
- 25 Taremi M, Khoshbaten M, Gachkar L, Ehsani-Ardakani MJ, Zali MR. Hepatitis E virus infection in hemodialysis patients: A seroepidemiological survey in Iran. *BMC Infect Dis*. 2005; **5**:36–39.
- 26 Mohtasham-Amiri Z., Ja'fari-Shakib A., Toorchi-Roodsari M. Seroprevalence of hepatitis C and risk factors in hemodialysis patients in Guilan province, Iran. *Payesh*. 2003; **2**:291–295.
- 27 Jabbari A, Besharat S, Khodabakhshi B. Hepatitis C in hemodialysis centers of golesan province, northeast of Iran (2005). *Hepat Mon*. 2008; **8**:61–65.
- 28 Mohammad-Alizadeh A, Ranjbar M, Seyfoleslami SAR. The frequency of hepatitis C in dialyse patients in hama-dan ekbatan hospital. *Iran J Infect Dis Trop Med*. 2002; **7**:27–34.
- 29 Saboor B, Boroomand P, Mehrabi Y, Ghanbari M, Zarrinfam H. Prevalence and risk factors of hepatitis C infection in hemodialysis patients (Kermanshah, 1999–2000). *Behbood. BEHBOOD*. 2003; **7**:60–66.
- 30 Samimirad K, Shahbaz B, Noroozi M, Mahmoodi M, Fayyaz-Vaseghi M. Prevalence of hepatitis C virus antibody and related risk factors among hemodialysis patients in Markazi province (2004). *Rahavard-E Danesh (J Arak Univ Med Sci)*. 2006; **9**:23–33.
- 31 Babaei M, Saadedin G. Comparison of prevalence of hepatitis C virus (HCV) infection among injection drug users (Idus) with other high risk groups: A case-control study of blood donors. Tehran, Iran: *4th Iranian International Congress of Gastroenterology & Hepatology and 2nd Congress of From Bed to Bench in Gastroenterology & Liver Disease*, 2004.
- 32 Ghomi HA, Sammak H, Forooghi SI, Sahami M, Bitarafan M. Review of Hepatitis B, C, and HIV prevalence in patients under hemodialysis in Qom Province in 1383. Tehran, Iran: *The 3rd Iranian Congress of Virology*, 2006.
- 33 Khadem-Ansari MH, Omrani M. Evaluation of diagnostic value of ELISA method (EIA) & PCR in diagnosis

- of hepatitis C virus in hemodialysis patients. *Hepat Mon.* 2006; **6**:19–23.
- 34 Statistical Center of Iran. *Overall Report of Iranian Census*. Iran: Statistical Center of Iran; 2007.
- 35 Azadegan-Ghomi H, Sammak H, Forooghi SI, Sahami M, Bitarafan M. Review of Hepatitis B, C, and HIV prevalence in patients under hemodialysis in Qom Province in 1383. *The 3rd Iranian Congress of Virology*. Tehran, Iran, 2006.
- 36 Souqiyeh MZ, Al-Attar MB, Zakaria H, Shaheen FA. Dialysis centers in the kingdom of Saudi Arabia. *Saudi J Kidney Dis Transpl.* 2001; **12**:293–304.
- 37 Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. *Med Princ Pract.* 2004; **13**:129–135.
- 38 Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: Serological diagnosis and genotyping. *J Med Microbiol.* 2002; **51**:700–704.
- 39 Khokhar N, Alam AY, Naz F, Mahmud SN. Risk factors for hepatitis C virus infection in patients on long-term hemodialysis. *J Coll Phys Surg Pak.* 2005; **15**:326–328.
- 40 Yakaryilmaz F, Gurbuz OA, Guliter S, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. *Ren Fail.* 2006; **28**:729–735.
- 41 Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. *Am J Kidney Dis.* 2005; **45**:684–689.
- 42 Reddy AK, Murthy KV, Lakshmi V. Prevalence of HCV infection in patients on haemodialysis: Survey by antibody and core antigen detection. *Indian J Med Microbiol.* 2005; **23**:106–110.
- 43 Qadi AA, Tamim H, Ameen G, et al. Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and molecular methods. *Am J Infect Control.* 2004; **32**:493–495.
- 44 Amin J, Gidding H, Gilbert G. Hepatitis C prevalence—a nationwide serosurvey. *Commun Dis Intell.* 2004; **28**:517–521.
- 45 Nemati E, Alavian SM, Taheri S, Moradi M, Pourfarziani V, Einollahi B. Hepatitis C virus infection among patients on hemodialysis: A report from a single center in Iran. *Saudi J Kidney Dis Transpl.* 2009; **20**:147–153.
- 46 Santana GO, Cotrim HP, Mota E, Parana R, Santana NP, Lyra L. [Antibodies to hepatitis C virus in patients undergoing hemodialysis in Salvador, BA, Brazil]. *Arq Gastroenterol.* 2001; **38**:24–31.
- 47 Hruby Z, Sliwinski J, Molin I, et al. High prevalence of antibodies to hepatitis C virus in three haemodialysis centres in south-western Poland. *Nephrol Dial Transplant.* 1993; **8**:740–743.
- 48 Souza KP, Luz JA, Teles SA, et al. Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: Serological and molecular profiles. *Mem Inst Oswaldo Cruz.* 2003; **98**:599–603.
- 49 Taskapan H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. *Clin Nephrol.* 2001; **55**:477–481.
- 50 Olmer M, Bouchouareb D, Zandotti C, de Micco P, de Lamballerie X. Transmission of the hepatitis C virus in an hemodialysis unit: Evidence for nosocomial infection. *Clin Nephrol.* 1997; **47**:263–270.
- 51 Fornis X, Fernandez-Llama P, Pons M, et al. Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit. *Nephrol Dial Transplant.* 1997; **12**:736–740.
- 52 Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. *Kidney Int.* 1994; **46**:504–511.
- 53 Alavian S, Bakhtiari S, Hajarizadeh B. Transfusion remains a risk factor for hepatitis C acquisition among patients on hemodialysis. *Transfus Today.* 2002; **50**:4.
- 54 Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. *Kidney Int.* 1997; **51**:981–999.
- 55 Busek SU, Baba EH, Tavares Filho HA, et al. Hepatitis C and hepatitis B virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil. *Mem Inst Oswaldo Cruz.* 2002; **97**:775–778.
- 56 Carrilho FJ, Moraes CR, Pinho JR, et al. Hepatitis B virus infection in haemodialysis centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. *BMC Public Health.* 2004; **4**:13–23.
- 57 Alavian SM. We need a new national approach to control hepatitis C: It is becoming too late. *Hepatitis Monthly.* 2008; **8**:89–93.
- 58 Karkar A. Hepatitis C in dialysis units: The Saudi experience. *Hemodial Int.* 2007; **11**:354–367.
- 59 Djukanovic L, Radovic M, Bakovic J, et al. Epidemiology of end-stage renal disease and current status of hemodialysis in Yugoslavia. *Int J Artif Organs.* 2002; **25**:852–859.
- 60 Silva LK, Silva MB, Rodart IF, et al. Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil. *Braz J Med Biol Res.* 2006; **39**:595–602.
- 61 Barril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: Effect of time, initiating HCV prevalence studies and adoption of isolation measures. *Antiviral Res.* 2003; **60**:129–134.
- 62 Carneiro MA, Martins RM, Teles SA, et al. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: A survey by polymerase chain reaction and serological methods. *Mem Inst Oswaldo Cruz.* 2001; **96**:765–769.
- 63 Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR Recomm Rep.* 2001; **50**(RR-5):1–43.

- 64 Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. *Clin Nephrol.* 2002; **57**:371–375.
- 65 Gilli P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. *Nephron.* 1995; **70**:301–306.
- 66 Calabrese G, Vagelli G, Guaschino R, Gonella M. Transmission of anti-HCV within the household of haemodialysis patients. *Lancet.* 1991; **338**:1466.
- 67 Harmankaya O, Cetin B, Obek A, Seber E. Low prevalence of hepatitis C virus infection in hemodialysis units: Effect of isolation? *Ren Fail.* 2002; **24**: 639–644.